Alx Oncology Holdings (ALXO) EPS (Weighted Average and Diluted) (2020 - 2026)
Alx Oncology Holdings recorded quarterly EPS (Weighted Average and Diluted) of -$0.17 in Q1 2026, up 59.52% quarter-over-quarter from -$0.42 in Q4 2025, and up 70.69% year-over-year from -$0.1 in Q1 2025.
Alx Oncology Holdings' EPS (Weighted Average and Diluted) history runs 7 years deep, the most recent figure standing at -$0.17 for Q1 2026.
- In Q1 2026, EPS (Weighted Average and Diluted) rose 70.69% year-over-year to -$0.17; the TTM figure through Mar 2026 stood at -$1.49 (up 39.18% YoY), while the FY2025 annual figure was -$1.9, up 26.36% from the prior year.
- EPS (Weighted Average and Diluted) came in at -$0.17 for Q1 2026 at Alx Oncology Holdings, up from -$0.42 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.17 in Q1 2026 to a low of -$1.24 in Q3 2023.
- A 5-year average of -$0.67 and a median of -$0.71 in 2024 frame the typical range for EPS (Weighted Average and Diluted).
- Across the five-year window, EPS (Weighted Average and Diluted) plunged 102.5% in 2022 and soared 70.69% in 2026, its largest moves.
- Alx Oncology Holdings' EPS (Weighted Average and Diluted) stood at -$0.75 in 2022, then declined by 22.67% to -$0.92 in 2023, then soared by 42.39% to -$0.53 in 2024, then gained by 20.75% to -$0.42 in 2025, then soared by 59.52% to -$0.17 in 2026.
- According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods registered -$0.17, -$0.42, and -$0.41 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | Alx Oncology Holdings | 189.80 Mn | 49.48 Mn | - | -0.17 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.17 |
| Dec 31, 2025 | -0.42 |
| Sep 30, 2025 | -0.41 |
| Jun 30, 2025 | -0.49 |
| Mar 31, 2025 | -0.58 |
| Dec 31, 2024 | -0.53 |
| Sep 30, 2024 | -0.58 |
| Jun 30, 2024 | -0.76 |
| Mar 31, 2024 | -0.71 |
| Dec 31, 2023 | -0.92 |
| Sep 30, 2023 | -1.24 |
| Jun 30, 2023 | -0.84 |
| Mar 31, 2023 | -0.74 |
| Dec 31, 2022 | -0.75 |
| Sep 30, 2022 | -0.87 |
| Jun 30, 2022 | -0.81 |
| Mar 31, 2022 | -0.60 |
| Dec 31, 2021 | -0.70 |
| Sep 30, 2021 | -0.61 |
| Jun 30, 2021 | -0.40 |
| Dec 31, 2020 | -1.02 |